A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs JNJ 63682918 (Primary) ; JNJ 63682931 (Primary) ; JNJ 65195208 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
- 29 Oct 2019 Planned End Date changed from 8 Apr 2021 to 30 Sep 2022.
- 11 Jun 2019 Planned End Date changed from 10 Mar 2021 to 8 Apr 2021.
- 19 Mar 2019 Planned End Date changed from 9 Sep 2020 to 10 Mar 2021.